List of videos

WEBINAR PTC Therapeutics - The 'PTC518' clinical trial updates

The European Huntington Association, in collaboration with PTC Therapeutics, organized a Webinar on the progress of their Phase 2 clinical trial which has just started here in Europe.
 
The trial and treatment approach was presented by professor Sarah Tabrizi from University College London. She explained everything about the compound ‘PTC518’.
After the presentation, Brian Beers, Global Project Leader and Amy-Lee Bredlau, Sr Dir Clinical Development from PTC, took part
in the discussion.

WEBINAR Prilenia - All you need to know about PROOF HD

The European Huntington Association, in collaboration with Prilenia, bring some updates about the Phase 3 trial where the investigational drug pridopidine is evaluated on HD patients. Close to 500 participants in North America and Europe are given either the active drug or placebo for more than one year. The recruitment went fast and smooth and we can expect to have the first results published sometime first half of 2023. The speakers told us about the background and mechanisms of Pridopidine, status for the trial and potential next steps. What will happen if the trial demonstrates effect? What if it does not?

listen to Michael Hayden, Andrew Feigin, Ralf Reilman and Anne Rosser in this Webinar.

Generation HD1 - What does the data tell us?

After several months digging into all the information collected in the Generation HD1 trial Roche is ready tell us about their findings in a webinar organized by EHA in collaboration with Roche and EHDN. Lauren Boak, PhD and Peter McColgan, MD, PhD from Roche will present the key findings from the Generation HD1 trial and the Tominersen program. Prof Anne Rosser, chair of EHDN, is participating in the following Q&A session and will help us understand the value of the findings and how we can make use of them for future work.

WAVE - What happened and what's next?

In this Zoom Webinar, Vissia Viglietta will be speaking on behalf of WAVE. She would explain the results and all the good work they have been doing in improving from the updates on PRECISION-HD1 and PRECISION-HD2 medical trials. WAVE would also present the promising approach that they are pursuing, the WVE-003 Project.

Huntington's Disease Treatment: Summary of 2020

With the help of Prof. Anne Rosser, Dr. Ralf Reilmann, Dr. Alzbeta Mühlbäck, and Astri Arnesen, president of the European Huntington Association, we summarised the biggest achievements in 2020 and made some predictions for 2021 regarding drug development in Huntington’s disease.